Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of CM512, a Bispecific Antibody Targeting TSLP and IL-13, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial